S.Korea's Boryung gets gov’t OK for diabetes drug Trubuddy

Two active ingredients create synergy in lowering blood sugar and treating cardiovascular disease

S.Korea's Boryung gets gov’t OK for diabetes drug Trubuddy
Ye-Na Kim 1
2023-09-06 11:35:20 yena@hankyung.com
Bio & Pharma

South Korea’s Boryung Corp. on Tuesday said it received approval from the Ministry of Food and Drug Safety for its new compound diabetes drug Trubuddy.

This new and improved medicine combines two active ingredients: the SGLT-2 inhibitor dapagliflozin and thiazolidinedione (TZD)-class pioglitazone. Receiving product approval were 10-30- and 10-15-milligram tablets.

Boryung said Trubuddy is the first domestically approved compound drug combining the two ingredients. Dapagliflozin and pioglitazone are used to combat Type 2 diabetes, which accounts for 90% of all forms of the disease.

Both lower blood sugar and create a strong synergy effect when administered together by combining their benefits and offsetting each other's side effects.

Each ingredient lowers blood sugar through its own mechanism to further lower blood sugar levels. Among eight factors that cause Type 2 diabetes, dapagliflozin improves insulin secretion disorder in the pancreas, raises glucose reabsorption in kidneys and reduces glucose absorption in muscles.

Pioglitazone improves insulin secretion disorder in the pancreas, raises glucose production in the liver, reduces glucose absorption in muscle and cuts glucose absorption in fatty tissue. So clinical tests found that the combination of both ingredients was more effective in lowering blood sugar.

In addition, this combination can reduce the risk of death from cardiovascular disease and lower the risk of myocardial infarction, stroke, kidney disease and high blood pressure. Boryung said it expects Trubuddy to improve indicators of non-alcoholic fatty liver disease as well as boost insulin sensitivity and beta cell function.

In side effects, the company said TZD-containing drugs cause edema (fluid retention) and weight gain but those with SGLT-2 inhibitors offset both effects. Both ingredients also incur low risk of hypoglycemia and do not directly stimulate the pancreas, making them safe and effective treatments for Type 2 diabetics.

Write to Ye-Na Kim at yena@hankyung.com

Boryung Pharma's sales surpass $311 mn in H1 2023

Boryung Pharma's sales surpass $311 mn in H1 2023

South Korea’s Boryung Corp. has alleviated the fear of falling behind in its sector expressed by its third-generation chairman Jay Kim Jung-Gyun, who has sped up the company’s space healthcare business.  Boryung’s management system is apparently settling down as CEO Chan

Dongwon backs out of Boryung Biopharma buyout deal

Dongwon backs out of Boryung Biopharma buyout deal

Boryung Biopharma's typhoid vaccine Zerotyph (Courtesy of Boryung Biopharma) Dongwon Industries Co., South Korea’s No. 1 canned tuna producer, has backed out of a deal estimated between $400 million and $500 million to buy Boryung Biopharma Co., a vaccine and novel drug developer, accordi

Boryung, Axiom Space to set up JV to explore space healthcare options

Boryung, Axiom Space to set up JV to explore space healthcare options

Boryung's lab at its Yesan plant (Courtesy of Boryung) South Korea's Boryung Corp., just decades ago a mom-and-pop pharmacy, will bring its healthcare expertise to space with Axiom Space Inc., a US commercial space station developer, dreaming to become a pioneer in the market for healthcare ser

Boryung signs deal with Stendhal to launch hypertension drug in Mexico

Boryung signs deal with Stendhal to launch hypertension drug in Mexico

Boryung, a South Korean pharmaceutical company, said on Monday it had signed a deal with Stendhal SA de CV, a Mexican medical specialty company, to launch its hypertension combination drug Dukarb Plus in Mexico this year.Dukarb Plus is part of Boryung’s Kanarb Family product line, which

S.Korea's Boryung receives EU GMP certification

S.Korea's Boryung receives EU GMP certification

Boryung's Yesan campus  South Korean pharmaceutical company Boryung announced that its production facility for anti-cancer injections in Yesan, South Chungcheong Province, has received European Union GMP certification. The facility underwent review by the German government's drug licensing

Boryung holds Care-in-Space Challenge in US for space healthcare startups

Boryung holds Care-in-Space Challenge in US for space healthcare startups

 NASA's last space shuttle Endeavor on display at the 1st Care-in-Space event  South Korea's pharmaceutical company Boryeong said on Friday that it held the first "Care-in-Space Challenge" event, a new space healthcare startup fostering program, in Los Angeles on Tuesday.The CIS Chall

(* comment hide *}